Search results
Results from the WOW.Com Content Network
The COVID-19 High-Performance Computing Consortium also aims to predict the spread of disease, model possible vaccines, and study thousands of chemical compounds to develop a COVID-19 vaccine or therapy. [37] [38] As of May 2020, the Consortium has used up 437 petaFLOPS of computing power.
COVID-19 vaccine clinical research uses clinical research to establish the characteristics of COVID-19 vaccines. These characteristics include efficacy , effectiveness , and safety. As of November 2022 [update] , 40 vaccines are authorized by at least one national regulatory authority for public use: [ 1 ] [ 2 ]
The Canadian government announced CA$275 million in funding for 96 research projects on medical countermeasures against COVID-19, including numerous vaccine candidates at Canadian universities, [179] [180] with plans to establish a "vaccine bank" of new vaccines for implementation if another COVID-19 outbreak occurs.
Today, a significant proportion of vaccines against viral diseases are created using nanotechnology. Solid lipid nanoparticles represent a novel delivery system for some vaccines against SARS-CoV-2 (the virus that causes COVID-19). [60] In recent decades, nanosized adjuvants have been widely used to enhance immune responses to targeted vaccine ...
COVI-VAC (codenamed CDX-005) is a COVID-19 vaccine developed by Codagenix, Inc. In December 2020, COVI-VAC started a Phase I clinical trial , involving 48 participants. The trial was scheduled to complete in June 2021, with results to be reported by May 2022.
Part of a series on the COVID-19 pandemic Scientifically accurate atomic model of the external structure of SARS-CoV-2. Each "ball" is an atom. COVID-19 (disease) SARS-CoV-2 (virus) Cases Deaths Timeline 2019 2020 January responses February responses March responses April responses May responses June responses July responses August responses September responses October responses November ...
Pfizer-BioNTech COVID-19 Vaccine (branded as Comirnaty) designed to provide protection against COVID-19 caused by infection with the SARS-CoV-2 virus (US emergency use authorization 2020). The mechanism is the same as Moderna (above) except that composition of the lipid nanoparticles are different, with Pfizer using the ionizable lipid known as ...
In October 2024, the CHMP gave a positive opinion to update the composition of Nuvaxovid, a vaccine to target the SARS-CoV-2 JN.1 variant of the virus that causes COVID-19 following the recommendations issued by EMA's Emergency Task Force to update COVID-19 vaccines for the 2024/2025 vaccination campaign.